Activation of AKT in feline mammary carcinoma: A new prognostic factor for feline mammary tumours

Veterinary Journal

Volumn 191, Issue 1, 2012, Pages 65-71

  Maniscalco, L ^a   Iussich, S ^a   Martin de las Mulas J ^b   Millan Y ^b   Biolatti, B ^a   Sasaki, N ^c   Nakagawa, T ^c   De Maria, R ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

AKT; Comparative oncology; Feline; Mammary tumour; Prognostic factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B;

ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST SURGERY; BREAST TUMOR; CANCER CELL CULTURE; CAT; CELL DEDIFFERENTIATION; CONTROLLED STUDY; DISEASE FREE INTERVAL; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; FOLLOW UP; GENE SEQUENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TUMOR RECURRENCE; WESTERN BLOTTING;

ANIMALS; CAT DISEASES; CATS; CELL LINE, TUMOR; FEMALE; IMMUNOHISTOCHEMISTRY; ITALY; MAMMARY NEOPLASMS, ANIMAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; FELIDAE;

EID: 84855562923     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2010.12.016     Document Type: Article

References (41)

1. Allred D., Harvey J., Berardo M., Clark G. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology 1998, 11:155-168.
2. Castagnaro M., Casalone C., Bozzetta E., De Maria R., Biolatti B., Caramelli M. Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas. Journal of Comparative Pathology 1998, 119:263-275.
3. De Maria R., Maggiora P., Biolatti B., Prat M., Comoglio P.M., Castagnaro M., Di Renzo M.F. Feline STK gene expression in mammary carcinomas. Oncogene 2002, 21:1785-1790.
4. De Maria R., Olivero M., Iussich S., Nakaichi M., Murata T., Biolatti B., Di Renzo M.F. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Research 2005, 65:907-912.
5. Duan C., Liimatta M.B., Bottum O.L. Insulin-like growth factor (IGF)-I regulates IGF-binding protein-5 gene expression through the phosphatidylinositol 3-kinase, protein kinase B/Akt, and p70 S6 kinase signaling pathway. Journal of Biological Chemistry 1999, 274:37147-37153.
6. Hahn K.A., Bravo L., Avenell J.S. Feline breast carcinoma as a pathologic and therapeutic model for human breast cancer. In Vivo 1994, 8:825-828.
7. Hamilton J.M., Else R.W., Forshaw P. Oestrogen receptors in feline mammary carcinomas. Veterinary Record 1976, 99:477-479.
8. Hayes A.A., Mooney S. Feline mammary tumors. Veterinary Clinics of North America: Small Animal Practice 1985, 15:513-520.
9. Klinghoffer R.A., Duckworth B., Valius M., Cantley L., Kazlauskas A. Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity. Molecular and Cellular Biology 1996, 16:5905-5914.
10. Lana S.E., Rutteman G.R., Withrow S.J. Tumors of the mammary gland. Small Animal Clinical Oncology 2007, 619-636. Saunders Elsevier, St. Louis, Missouri, USA. S.J. Withrow, E.G. MacEwen (Eds.).
11. Luo J., Manning B., Cantley L. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4:257-262.
12. Martín de las Mulas J., Millán Y., Bautista M., Pérez J., Carrasco L. Oestrogen and progesterone receptors in feline fibroadenomatous change: an immunohistochemical study. Research in Veterinary Science 2000, 68:15-21.
13. Martín de las Mulas J., van Niel M., Millan Y., Blankenstein M.A., van Mil F., Misdorp W. Immunohistochemical analysis of estrogen receptors in feline mammary gland benign and malignant lesions: comparison with biochemical assay. Domestic Animal Endocrinology 2000, 18:111-125.
14. Martín de las Mulas J.M., Van Niel M., Millan Y., Ordas J., Blankenstein M.A., Van Mil F., Misdorp W. Progesterone receptors in normal, dysplastic and tumourous feline mammary glands. Comparison with oestrogen receptors status. Research in Veterinary Science 2002, 72:153-161.
15. Martin P.M., Cotard M., Mialot J.P., Andre F., Raynaud J.P. Animal models for hormone-dependent human breast cancer. Relationship between steroid receptor profiles in canine and feline mammary tumors and survival rate. Cancer Chemotherapy and Pharmacology 1984, 12:13-17.
16. Millanta F., Calandrella M., Citi S., Della Santa D., Poli A. Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential. Veterinary Pathology 2005, 42:30-34.
17. Millanta F., Calandrella M., Vannozzi I., Poli A. Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prognostic significance. Veterinary Record 2006, 158:821-824.
18. Misdorp W., Weijer K. Animal model of human disease: breast cancer. American Journal of Pathology 1980, 98:573-576.
19. Misdorp W., Else W., Hellmen E., Lipscomb T.P. Histological classification of the mammary tumours of the dog and the cat. World Health Organization International Histological Classification of Tumors of the Domestic Animals, second series, vol. 7 1999, 11-56. Armed Forces Institute of Pathology, Washington, DC. F.Y. Schulman (Ed.).
20. Munson L., Moresco A. Comparative pathology of mammary gland cancers in domestic and wild animals. Breast Disease 2007, 28:7-21.
21. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cellular Signalling 2002, 14:381-395.
22. Novosad C., Bergman P., O'Brien M., McKnight J., Charney S., Selting K., Graham J., Correa S., Rosenberg M., Gieger T. Retrospective evaluation of adjunctive doxorubicin for the treatment of feline mammary gland adenocarcinoma: 67 cases. Journal of the American Animal Hospital Association 2006, 42:110-120.
23. Okano J., Gaslightwala I., Birnbaum M.J., Rustgi A.K., Nakagawa H. Akt/Protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. Journal of Biological Chemistry 2000, 275:30934-30942.
24. Ordas J., Millan Y., Dios R., Reymundo C., de las Mulas J.M. Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. BMC Cancer 2007, 7:179.
25. Park S., Kim S. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. Oncology Reports 2007, 18:139-143.
26. Perez-Tenorio G., Stal O., Group S.E.S.B.C. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. British Journal of Cancer 2002, 86:540-545.
27. Petterino C., Ratto A., Podestà G., Drigo M., Pellegrino C. Immunohistochemical evaluation of STAT3-p-tyr705 expression in feline mammary gland tumours and correlation with histologic grade. Research in Veterinary Science 2007, 82:218-224.
28. Rasotto R., Caliari D., Castagnaro M., Zanetti R., Zappulli V. An Immunohistochemical study of HER-2 expression in feline mammary tumours. Journal of Comparative Pathology 2010, 10.1016/j.jcpa.2010.08.010.
29. Ressel L., Millanta F., Caleri E., Innocenti V., Poli A. Reduced PTEN protein expression and its prognostic implications in canine and feline mammary tumors. Veterinary Pathology 2009, 46:860-868.
30. Rutteman G.R., Blankenstein M.A., Minke J., Misdorp W. Steroid receptors in mammary tumours of the cat. Acta Endocrinologica (Copenhagen) 1991, 125:32-37.
31. Seow H., Yip W., Loh H., Ithnin H., Por P., Rohaizak M. Immunohistochemical detection of phospho-Akt, phospho-BAD, HER2 and oestrogen receptors alpha and beta in Malaysian breast cancer patients. Pathology and Oncology Research 2010, 16:239-248.
32. Shtilbans V., Wu M., Burstein D.E. Current overview of the role of Akt in cancer studies via applied immunohistochemistry. Annals of Diagnostic Pathology 2008, 12:153-160.
33. Stoica G.E., Franke T.F., Moroni M., Mueller S., Morgan E., Iann M.C., Winder A.D., Reiter R., Wellstein A., Martin M.B., Stoica A. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 2003, 22:7998-8011.
34. Sun M., Wang G., Paciga J.E., Feldman R.I., Yuan Z.Q., Ma X.L., Shelley S.A., Jove R., Tsichlis P.N., Nicosia S.V., Cheng J.Q. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. American Journal of Pathology 2001, 159:431-437.
35. Takauji S., Watanabe M., Uyama R., Nakagawa T., Miyajima N., Mochizuki M., Nishimura R., Sugano S., Sasaki N. Expression and subcellular localization of E-cadherin, alpha-catenin, and beta-catenin in 8 feline mammary tumor cell lines. Journal of Veterinary Medical Science 2007, 69:831-834.
36. Tokunaga E., Kimura Y., Mashino K., Oki E., Kataoka A., Ohno S., Morita M., Kakeji Y., Baba H., Maehara Y. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 2006, 13:137-144.
37. Tokunaga E., Oki E., Egashira A., Sadanaga N., Morita M., Kakeji Y., Maehara Y. Deregulation of the Akt pathway in human cancer. Current Cancer Drug Targets 2008, 8:27-36.
38. Trimboli A., Cantemir-Stone C., Li F., Wallace J., Merchant A., Creasap N., Thompson J., Caserta E., Wang H., Chong J., Naidu S., Wei G., Sharma S., Stephens J., Fernandez S., Gurcan M., Weinstein M., Barsky S., Yee L., Rosol T., Stromberg P., Robinson M., Pepin F., Hallett M., Park M., Ostrowski M., Leone G. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009, 461:1084-1091.
39. Viste J., Myers S., Singh B., Simko E. Feline mammary adenocarcinoma: tumor size as a prognostic indicator. Canadian Veterinary Journal 2002, 43:33-37.
40. Wu Y., Mohamed H., Chillar R., Ali I., Clayton S., Slamon D., Vadgama J.V. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Research 2008, 10:R3.
41. Zhou X., Tan M., Stone Hawthorne V., Klos K., Lan K., Yang Y., Yang W., Smith T., Shi D., Yu D. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clinical Cancer Research 2004, 10:6779-6788.